rs7125552 — EMSY EMSY Haplotype Partner Allergy Variant

EMSY Haplotype Structure — The Hidden Context Behind the 11q13.5 Allergy Signal

The well-known rs7927894 T allele at chromosome 11q13.5 is one of the most replicated atopic dermatitis susceptibility signals in the human genome — but the full story of this locus requires a second variant. Ponińska et al. (2017)¹¹ Ponińska et al. (2017)
Ponińska et al., PLoS One 2017 — 2,437 participants from the ECAP (Epidemiology of Allergic Diseases in Poland) cohort including subjects with atopic dermatitis, atopic asthma, and persistent allergic rhinitis plus matched controls showed that the risk conferred by rs7927894 T is not carried by the T allele alone: it is haplotype-dependent, and specifically requires the G allele at rs7125552 to manifest. Without G at this position, the rs7927894 T allele's association with atopic dermatitis and allergic rhinitis disappears.

This kind of haplotype dependency is clinically meaningful: it means that genotyping rs7927894 alone gives an incomplete picture of this locus's risk contribution. rs7125552 is the contextual marker that defines whether the risk haplotype is complete.

The Mechanism

rs7125552 sits at position 76,500,050 on chromosome 11 (GRCh38, NC_000011.10:g.76500050G>A), approximately 90 kilobases upstream of rs7927894 (position 76,590,272) within the EMSY gene body. Both variants lie within the same topologically associating domain (TAD) that encompasses EMSY and LRRC32²² EMSY and LRRC32
EMSY (C11orf30) is a chromatin regulatory protein that epigenetically suppresses skin barrier genes including filaggrin and ceramide synthesis enzymes; LRRC32 encodes GARP, a TGF-β receptor complex component on regulatory T cells — both genes contribute to allergic susceptibility through distinct mechanisms at the same genomic address.

The intronic location of rs7125552 within EMSY suggests it acts as a regulatory element — likely a cis-regulatory variant that interacts with the rs7927894 regulatory signal to form the complete functional haplotype. Neither variant alone captures the full effect; together, they define a chromatin state in which EMSY expression is maximally elevated. Higher EMSY activity epigenetically silences filaggrin, filaggrin-2, and long-chain ceramide synthesis enzymes — the proteins that build and maintain the skin's physical barrier against allergen entry and water loss. The resulting barrier deficit is the upstream event that permits allergen sensitisation and initiates the atopic march.

The Evidence

The Ponińska et al. haplotype analysis across 2,437 ECAP cohort participants is the key evidence for this variant's role. In single-SNP analysis, rs7125552 showed no significant independent association with atopic dermatitis (OR=1.08, p=0.49). Its importance emerges at the haplotype level: the TG haplotype (T at rs7927894, G at rs7125552) carried an OR of 1.92 (p=0.00021) for atopic dermatitis and OR=1.32 (p=0.023) for persistent allergic rhinitis. In contrast, the TA haplotype (T at rs7927894, A at rs7125552) had OR=1.12 (p=0.36) — statistically indistinguishable from no effect. This demonstrates that rs7125552 G is not merely a passenger — it is structurally required for the allergy risk haplotype to be functional.

The 11q13.5 locus was confirmed as a key atopic march locus in a 2015 meta-analysis³³ 2015 meta-analysis
Marenholz et al., Nat Commun 2015 — 12 populations, 2,428 combined eczema+asthma cases and 17,034 controls and in the large Paternoster et al. meta-GWAS⁴⁴ Paternoster et al. meta-GWAS
Nat Genet 2011 — 5,606 cases and 20,565 controls in discovery; 5,419 and 19,833 in replication. These studies replicate the 11q13.5 association; the Ponińska work adds the mechanistic detail that the haplotype — not a single SNP — is the functional unit.

The mechanistic basis for why this haplotype matters was established by Elias and Brown (2019)⁵⁵ Elias and Brown (2019)
J Allergy Clin Immunol — siRNA knockdown and overexpression in organotypic skin models, plus proteomics and lipid analysis, plus AD biopsy immunohistochemistry: EMSY knockdown enhances barrier gene expression (filaggrin, filaggrin-2, long-chain ceramides), while EMSY overexpression suppresses these markers. AD skin biopsies show elevated nuclear EMSY staining, consistent with the risk haplotype driving excessive transcriptional repression of barrier genes.

Practical Actions

The actionable implications of rs7125552 mirror those of its haplotype partner rs7927894, because the two variants define the same functional unit. Carriers of G at rs7125552 who also carry T at rs7927894 are on the complete high-risk haplotype (TG), with an approximately twofold increased risk for atopic dermatitis. The primary intervention targets the EMSY-mediated barrier deficit: ceramide-containing emollient as proactive barrier support, avoidance of detergents that strip ceramides, and surveillance for atopic march progression (eczema → food allergy → respiratory allergy).

Carriers of AA at rs7125552 represent the minority (approximately 9%) who carry two copies of the haplotype-breaking A allele — these individuals appear protected from the rs7927894 T risk effect even if they carry T alleles at that position.

Interactions

The central interaction is the cis-haplotype with rs7927894: these two variants at 11q13.5 are best interpreted as a functional unit rather than as independent signals. The high-risk haplotype is T (rs7927894) + G (rs7125552); the protective configuration requires A at rs7125552.

Beyond the cis interaction, the 11q13.5 locus interacts with filaggrin loss-of-function variants (rs61816766 and rs12123821) through converging effects on skin barrier integrity. In paediatric cohorts, carrying both the 11q13.5 risk haplotype and a filaggrin null mutation raised atopic dermatitis odds to OR=16.41 — far beyond either variant alone. The IL13 variant rs20541 operates from the immune activation side of the same atopic phenotype and compounds the total risk carried by 11q13.5 haplotype carriers.